ClinicalTrials.gg
RecruitingNCT07309367Updated Dec 30, 2025

Web-based Advance Care Planning Intervention for Patients With Kidney Failure on Dialysis: Pilot Testing of 'My Voice'

An interventional study of My Voice website intervention with patient and caregiver modules in Kidney Failure, Chronic Therapy; Hemodialysis, sponsored by Duke-NUS Graduate Medical School. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Duke-NUS Graduate Medical School · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

'My Voice' is a website intervention developed to enable advance care planning (ACP) conversations for patients with kidney disease on dialysis, educate patients on their illness, help identify their goals and preferences for EOL care, and coaches them on how to speak with their HCPs and loved ones. This study aims to evaluate if 'My Voice' intervention improves quality of ACP conversations between patients and providers, and patients and family carers; improves patient's knowledge about kidney failure, engagement in ACP and preparedness for future end of life care compared to usual practices for ACP in dialysis centres.

02

Conditions studied

  • Kidney Failure, Chronic Therapy; Hemodialysis

Browse trials for

Keywords

  • Advance care planning
  • Web intervention
  • Dialysis withdrawal
03

In context

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

This study's planned enrollment of 100 is above the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Duke-NUS Graduate Medical School is the lead sponsor of 63 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: For patients

  • Singapore citizens or permanent residents; aged 21 years (age of majority) or older
  • CKD stage 5; receiving dialysis
  • Identified as eligible for SIC by NKF HCPs based on one or more of the following:

    1. clinical deterioration with a terminal condition or
    2. intolerability to dialysis or
    3. having two or more unplanned hospitalizations for renal complications in the past 6 months (from medical records); or
    4. known to palliative care or under conservative care as indicated in the discharge summary or
    5. poor functional status indicated by the Fragility Assessment for Elders (FIFE) score >4
  • Normal cognitive function as indicated by Mini Mental Scale Examination () score of 24 or more (based on medical record)
  • Able to speak and read English, Mandarin or Malay
  • Agreeable to be audio-recorded

Inclusion Criteria: For caregivers

  • Aged 21 years old and above
  • Family caregivers of the patients recruited i.e. Caregiver primarily involved in providing care, ensuring provision of care, and/or in making decisions regarding patient's care, with no expectation of financial compensation
  • Able to speak and read English, Mandarin or Malay
  • Have a phone and/or an electronic device with internet access.
  • Agreeable to be audio-recorded

Exclusion Criteria: For Patients

  • Patients with cognitive impairment or serious mental illness will be excluded
  • Patients who had prior serious illness conversations (SIC) will be excluded
  • Are not easily contactable via mobile phone or landline

Exclusion Criteria: For Caregivers

  • Those who are foreign domestic workers/maids
  • Are not easily contactable via mobile phone or landline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Patients will view My Voice website intervention and complete patient module. They will also receive standard of care for advance care planning \[namely serious illness conversation (SIC)\] with the health care provider at the dialysis centers. Caregivers will view My Voice website intervention and complete caregiver module.

    Other: My Voice website intervention with patient and caregiver modules

  • No intervention
    Usual care group

    Patients will receive standard of care for advance care planning -namely the serious illness conversation (SIC) with the health care provider at the dialysis centres. Caregivers will receive no intervention.

Interventions

  • OtherMy Voice website intervention with patient and caregiver modules

    'My Voice' is an interactive web-based ACP intervention tailored for patients with kidney failure on dialysis, and their caregivers, and includes patient and caregiver modules. Patient module has 6 steps consisting of a series of videos, value-clarification exercise (VCE) identifying goals and values for care, and knowledge quiz, and a summary My Voice document that is generated shared with patients, designated surrogates and HCPs. Automated reminders are sent to revisit My Voice. Caregiver module has 4 steps with videos and quiz, with access to their loved one's summary My Voice document containing goals of care and values.

06

What researchers measure

Primary outcomes

  1. Quality of ACP conversations (serious illness conversations) between patients and physicians/health care providers

    Quality of ACP conversations will be measured using a scoring sheet developed for the study. One point will be given for every SICG topic discussed with score min to max of 0 to 13. Higher scores indicate higher quality.

    Time frame: Post baseline and within 8 weeks

Other outcomes

  1. Change in kidney disease and dialysis knowledge scores

    Collected using knowledge questions designed by the research team. Higher scores indicate higher knowledge

    Time frame: Baseline to 8 weeks

  2. Change in ACP engagement

    Using the 9-item Advance care planning engagement scale. 9 to 45 (Min to Max) value, with higher value indicating higher engagement

    Time frame: Baseline to 8 weeks

  3. Change in patient preparedness

    Assessed using Preparedness for end-of-life decision-making scale. 20 to 80 (min to max) scores, with higher scores indicating better preparedness

    Time frame: Baseline to 8 weeks

  4. Change in proportion of patients who had ACP conversations with family caregivers/spokesperson

    Based on self-reported number of ACP conversations collected in the survey

    Time frame: Baseline and 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 118 non-industry interventional studies with no phase under Renal Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 11 months is below that.

Counting every sponsor, half of 149 studies reached it within 22 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Dec 30, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309367
Lead sponsor
Duke-NUS Graduate Medical School
Collaborators
National Kidney Foundation, Singapore
Responsible party
Chandrika Ramakrishnan (Research Fellow, Duke-NUS Graduate Medical School) — Principal investigator
First posted
Dec 30, 2025
Start date
Oct 2, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Chandrika Ramakrishnan, MBBS; MPH
Contact
chandrika.ramky@duke-nus.edu.sg
+6566011253

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion